Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Tonix Pharmaceuticals Holding Corp. buy me8

Start price
€10.99
13.06.22 / 0%
Target price
€12.50
13.06.23
Performance (%)
-0.18%
End price
€10.97
25.06.22
Summary
This prediction ended on 25.06.22 with a price of €10.97. During the runtime of the prediction for Tonix Pharmaceuticals Holding Corp. the price only changed by -0.18%. This prediction was marked as speculative and is excluded from me8's performance statistics.
Performance without dividends (%)
Name 1w 1m 1y
Tonix Pharmaceuticals Holding Corp. - - -
iShares Core DAX® -0.992% -3.231% 11.661%
iShares Nasdaq 100 -0.225% -3.339% 36.491%
iShares Nikkei 225® -0.736% -7.859% 18.597%
iShares S&P 500 -0.509% -2.979% 26.341%

According to me8 what are the pros and cons of Tonix Pharmaceuticals Holding Corp. for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Differentiated customer and product portfolio
Cons
Little innovation

Comments by me8 for this prediction

In the thread Tonix Pharmaceuticals Holding diskutieren

Buy Tonix Pharma. Holding Corp.

Prediction Buy
Perf. (%) -0.18%
Target price 2.000
Change
Ends at 13.06.23

Kursziel gesetzt auf 2,0

In the thread Trading Tonix Pharmaceuticals Holding Corp.
Prediction Buy
Perf. (%) -0.18%
Target price 2.000
Change
Ends at 13.06.23

Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.

Stopped prediction by me8 for Tonix Pharmaceuticals Holding Corp.

buy
Tonix Pharmaceuticals Holding Corp.

Start price
Target price
Perf. (%)
€8.56
25.07.22
€12.50
25.07.23
26.95%
26.07.22

Could be worthwhile Investment >10% per year
Differentiated customer and product portfolio
Little innovation
buy
Tonix Pharmaceuticals Holding Corp.

Start price
Target price
Perf. (%)
€172.00
07.05.20
-
16.05.20
-28.49%
16.05.20

Could be worthwhile Investment >10% per year
Differentiated customer and product portfolio
Little innovation